Eisner, Mark D.
FibroGen, Inc.,
United States
2025 Rank: 28127
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Respiratory System
SubField 2:
Emergency & Critical Care Medicine
Rank in SubField 1: 268 out of 68788 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 28127 | 29337 |
| Total Cites | 14739 | 16616 |
| H-index | 64 | 69 |
| Hm-index | 21 | 22 |
| Number of Single Authored Papers | 17 | 17 |
| Total Cites to Single Authored Papers | 236 | 249 |
| Number of Single+First Authored Papers | 71 | 71 |
| Total Cites to Single+First Authored Papers | 4427 | 4877 |
| Number of Single+First+Last Authored Papers | 99 | 99 |
| Total Cites to Single+First+Last Authored Papers | 7080 | 7717 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 12320 | 13059 |
| Ratio of Total Citations to Distinct Citing Papers | 1.20 | 1.27 |
| Self-Citation Percentage |
11.30%
|
|
Eisner, Mark D.
Genentech, Inc,
United States
2024 Rank: 25987
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Respiratory System
SubField 2:
Emergency & Critical Care Medicine
Rank in SubField 1: 245 out of 65702 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 25987 | 26910 |
| Total Cites | 14515 | 16440 |
| H-index | 65 | 70 |
| Hm-index | 21 | 22 |
| Number of Single Authored Papers | 17 | 17 |
| Total Cites to Single Authored Papers | 228 | 241 |
| Number of Single+First Authored Papers | 71 | 71 |
| Total Cites to Single+First Authored Papers | 4232 | 4678 |
| Number of Single+First+Last Authored Papers | 99 | 99 |
| Total Cites to Single+First+Last Authored Papers | 6775 | 7402 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 12036 | 12783 |
| Ratio of Total Citations to Distinct Citing Papers | 1.21 | 1.29 |
| Self-Citation Percentage |
11.71%
|
|
Eisner, Mark D.
Genentech, Inc,
United States
2023 Rank: 26319
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Respiratory System
SubField 2:
Allergy
Rank in SubField 1: 259 out of 62427 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 26319 | 27098 |
| Total Cites | 13051 | 14806 |
| H-index | 61 | 66 |
| Hm-index | 21 | 22 |
| Number of Single Authored Papers | 17 | 17 |
| Total Cites to Single Authored Papers | 226 | 237 |
| Number of Single+First Authored Papers | 70 | 70 |
| Total Cites to Single+First Authored Papers | 4067 | 4500 |
| Number of Single+First+Last Authored Papers | 97 | 97 |
| Total Cites to Single+First+Last Authored Papers | 6309 | 6923 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 10994 | 11690 |
| Ratio of Total Citations to Distinct Citing Papers | 1.19 | 1.27 |
| Self-Citation Percentage |
11.85%
|
|
Eisner, Mark D.
Genentech Incorporated,
United States
2022 Rank: 24910
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Respiratory System
SubField 2:
Allergy
Rank in SubField 1: 248 out of 60663 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 24910 | 26184 |
| Total Cites | 12197 | 13896 |
| H-index | 60 | 64 |
| Hm-index | 20 | 21 |
| Number of Single Authored Papers | 17 | 17 |
| Total Cites to Single Authored Papers | 216 | 227 |
| Number of Single+First Authored Papers | 70 | 70 |
| Total Cites to Single+First Authored Papers | 3832 | 4259 |
| Number of Single+First+Last Authored Papers | 97 | 97 |
| Total Cites to Single+First+Last Authored Papers | 5921 | 6524 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 10256 | 10928 |
| Ratio of Total Citations to Distinct Citing Papers | 1.19 | 1.27 |
| Self-Citation Percentage |
12.23%
|
|
Eisner, Mark D.
Genentech Incorporated,
United States
2021 Rank: 24646
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Respiratory System
SubField 2:
Allergy
Rank in SubField 1: 251 out of 60468 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 24646 | 25287 |
| Total Cites | 11749 | 13358 |
| H-index | 60 | 63 |
| Hm-index | 19 | 21 |
| Number of Single Authored Papers | 17 | 17 |
| Total Cites to Single Authored Papers | 212 | 223 |
| Number of Single+First Authored Papers | 70 | 70 |
| Total Cites to Single+First Authored Papers | 3712 | 4117 |
| Number of Single+First+Last Authored Papers | 97 | 97 |
| Total Cites to Single+First+Last Authored Papers | 5736 | 6310 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 9859 | 10500 |
| Ratio of Total Citations to Distinct Citing Papers | 1.19 | 1.27 |
| Self-Citation Percentage |
12.05%
|
|
Eisner, Mark D.
Genentech Incorporated,
United States
2020 Rank: 23415
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Respiratory System
SubField 2:
Allergy
Rank in SubField 1: 231 out of 52718 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 23415 | 24107 |
| Total Cites | 10802 | 12345 |
| H-index | 57 | 61 |
| Hm-index | 19 | 21 |
| Number of Single Authored Papers | 17 | 17 |
| Total Cites to Single Authored Papers | 205 | 216 |
| Number of Single+First Authored Papers | 70 | 70 |
| Total Cites to Single+First Authored Papers | 3453 | 3851 |
| Number of Single+First+Last Authored Papers | 97 | 97 |
| Total Cites to Single+First+Last Authored Papers | 5304 | 5866 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 9027 | 9619 |
| Ratio of Total Citations to Distinct Citing Papers | 1.20 | 1.28 |
| Self-Citation Percentage |
12.50%
|
|
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.